Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;25(6):e377-e378.
doi: 10.1111/hae.13855. Epub 2019 Oct 2.

Mechanistic rationale for factor XIII cotreatment in haemophilia

Joan D Beckman  1 , Alisa S Wolberg  2
Affiliations

Mechanistic rationale for factor XIII cotreatment in haemophilia

Joan D Beckman et al. Haemophilia. 2019 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures of Conflicts of Interest

The authors have no other conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Abdulrehman J, Houston BL, Chaudhry H, Rivard G-E, Teitel JM, Sholzberg M. Acquired haemophilia A and concomitant factor XIII consumption. Haemophilia. 2019;25(3):e180–e183. - PubMed
    1. Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood. 2010;116(25):5734–5737. - PubMed
    1. Ng C, Silliman CC, Pearl G, Smith W, Manco-Johnson M, Wang M. Treatment of refractory hemorrhage with Factor XIII in a patient with hemophilia A with inhibitor. Pediatr Blood Cancer. 2013;60(7):E23–25. - PubMed
    1. Gringeri A, Fischer K, Karafoulidou A, Klamroth R, Lopez-Fernandez MF, Mancuso E. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia. 2011;17(4):630–635. - PubMed
    1. Beckman JD, Holle LA, Wolberg AS. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin alpha-chain crosslinking. J Thromb Haemost 2018;16(1):131–141. - PMC - PubMed